Study of APL2 for adults with FSGS kidney disease
Part of Kidney & urinary clinical trials.
This study tests an investigational medicine called APL2 for people with a kidney disease called focal segmental glomerulosclerosis (FSGS). The goal is to see if APL2 can reduce the amount of protein leaking into the urine and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (ages 12–17 may be included in later phases, but not initially).
- Your weight must be between 30 and 100 kg (about 66 to 220 pounds).
- You must have a diagnosis of primary, genetic, or undetermined FSGS confirmed by a kidney biopsy (or a known genetic cause in phase 3).
- You must have significant protein in your urine (at least 1.5 grams per day) and a urine protein-to-creatinine ratio of 1.5 or higher.
- Your kidney function must be at a certain level (eGFR of 25 mL/min/1.73 m² or higher).
- Your current FSGS treatment must be stable for at least 12 weeks before you join, and you must not be planning any changes to it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether DMX-200 is safer and works better than placebo for people with FSGS who are already on (or can switch to) an ARB blood-pressure/kidney-protection medicine. It also looks at side effects over a long follow-up period.
This trial tests whether the diabetes drug metformin can help people with a kidney disease called FSGS, by activating a cell-protecting pathway. Participants will take metformin or a placebo along with their usual steroid treatment.
This trial tests if a new medicine called BI 764198 can help people with a kidney condition called FSGS. It looks at whether the drug can reduce protein in the urine and protect kidney function.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This trial tests an investigational drug called praliciguat for people with FSGS, a kidney disease that causes scarring in the kidney filters. The goal is to see if praliciguat can help reduce protein in the urine and protect kidney function.
This trial collects medical data and blood/urine samples from patients with minimal change disease or focal segmental glomerulosclerosis (FSGS) to better understand how the immune system damages kidney cells.
Hear when a new FSGS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.